Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 7, 2026, 1:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,190 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pharmacokinetic Clear all
Active, not recruiting Phase 1 Interventional

A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)

NCT02942290
View directory record Official record
Conditions
Myelodysplastic Syndromes (MDS)
Interventions
Azacitidine, Venetoclax
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
13
States / cities
Tucson, Arizona • Chicago, Illinois • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Jun 7, 2026, 1:30 PM EDT
Completed Phase 1 Interventional

Phase I, Multicenter, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM01183 in Patients With Advanced Solid Tumors

NCT00877474
View directory record Official record
Conditions
ADVANCED SOLID TUMORS
Interventions
PM01183
Drug
Lead sponsor
PharmaMar
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Jun 7, 2026, 1:30 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin In Alpha1-antitrypsin Deficient Adults

NCT00295061
View directory record Official record
Conditions
Alpha 1-Antitrypsin Deficiency
Interventions
Alpha-1 MP, alpha-1 proteinase inhibitor (human)
Drug
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
8
States / cities
Denver, Colorado • Gainesville, Florida • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2014 · Synced Jun 7, 2026, 1:30 PM EDT
Terminated Phase 1 Interventional

A Study to Evaluate Safety, Pharmacokinetic, and Biological Activity of INCB059872 in Subjects With Sickle Cell Disease

NCT03132324
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
INCB059872
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
7
States / cities
Miami, Florida • Tamarac, Florida • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2019 · Synced Jun 7, 2026, 1:30 PM EDT
Completed Phase 1Phase 2 Interventional

Pharmacokinetic Study of MTC896 Gel in Subjects With Acne

NCT02293018
View directory record Official record
Conditions
Acne Vulgaris
Interventions
0.75% (w/w) MTC896 Gel Once Daily, 0.75% (w/w) MTC896 Gel Twice Daily, 1.5% (w/w) MTC896 Gel Once Daily
Drug
Lead sponsor
Mimetica Pty Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
3
States / cities
Austin, Texas • College Station, Texas • Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Apr 16, 2015 · Synced Jun 7, 2026, 1:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Study of 5 and 10 mg Corplex™ Donepezil TDS Compared to 10 mg Aricept® in Healthy Volunteers

NCT04617782
View directory record Official record
Conditions
Healthy Subjects
Interventions
Donepezil TDS, Aricept
Combination Product · Drug
Lead sponsor
Corium, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jun 7, 2026, 1:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic and Safety Study of E7080 in Subjects With Mild (10 mg), Moderate (10 mg), and Severe Hepatic Impairment (5 mg) and Normal Hepatic Function (10 mg)

NCT02421042
View directory record Official record
Conditions
Hepatic Impairment, Hepatic Function
Interventions
Lenvatinib
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
5
States / cities
Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated May 4, 2015 · Synced Jun 7, 2026, 1:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic Study to Assess the Influence of Simultaneous CYP3A4 and P-glycoprotein Inhibition on E7080 Pharmacokinetics Following Single Dose Oral Administration of 5 mg E7080 to Healthy Volunteers

NCT02198170
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ketoconazole-placebo, placebo-ketoconazole
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Feb 12, 2015 · Synced Jun 7, 2026, 1:30 PM EDT
Completed Phase 1 Interventional

SU5416 and Doxorubicin in Treating Patients With Stage IIIB or Stage IV Inflammatory Breast Cancer

NCT00005822
View directory record Official record
Conditions
Breast Cancer
Interventions
doxorubicin hydrochloride, semaxanib, conventional surgery, radiation therapy, tamoxifen
Drug · Procedure · Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 10, 2010 · Synced Jun 7, 2026, 1:30 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Use of Factor XIII Concentrate in Patients With Inherited FXIII Deficiency

NCT00883090
View directory record Official record
Conditions
Factor XIII Deficiency
Interventions
FXIII Concentrate (Human)
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
5
States / cities
Dothan, Alabama • Orange, California • San Francisco, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2012 · Synced Jun 7, 2026, 1:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic Study to Evaluate the Dose-Proportionality of Tramadol (ULTRAM) Extended-Release (ER) in Healthy Participants

NCT01800682
View directory record Official record
Conditions
Healthy
Interventions
Tramodol Extended-Release (ER)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 27, 2013 · Synced Jun 7, 2026, 1:30 PM EDT
Completed Phase 1 Interventional

The Safety, Pharmacokinetic and Pharmacodynamic Effect of KA2237 (PI3 Kinase p110β/δ Inhibitor) In B Cell Lymphoma

NCT02679196
View directory record Official record
Conditions
Lymphoma, B Cell
Interventions
KA2237
Drug
Lead sponsor
Karus Therapeutics Limited
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2019 · Synced Jun 7, 2026, 1:30 PM EDT
Completed Phase 1 Interventional

A Study of CI-1012 in HIV-Infected Patients

NCT00002196
View directory record Official record
Conditions
HIV Infections
Interventions
CI-1012
Drug
Lead sponsor
Parke-Davis
Industry
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
4
States / cities
Palm Springs, California • San Francisco, California • Maitland, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jun 7, 2026, 1:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Genotype Stratified Pharmacokinetic Study of Montelukast

NCT01086527
View directory record Official record
Conditions
Asthma
Interventions
10 mg tablet of montelukast (Singulair)
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
7 Years to 35 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 9, 2025 · Synced Jun 7, 2026, 1:30 PM EDT
Completed Phase 1 Interventional

A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function

NCT01513083
View directory record Official record
Conditions
Breast Cancer
Interventions
trastuzumab emtansine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
4
States / cities
Fort Myers, Florida • Detroit, Michigan • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Jun 7, 2026, 1:30 PM EDT
Completed Phase 1 Interventional

A Pharmacokinetics, Pharmacodynamics and Safety Study of Rabeprazole in New Born Infants With Gastroesophageal Reflux Disease (GERD)

NCT00855361
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Rabeprazole sodium
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
Up to 44 Weeks
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
10
States / cities
Orange, California • Washington D.C., District of Columbia • Augusta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2013 · Synced Jun 7, 2026, 1:30 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Ethnobridging TriaL of AGA2118 in Healthy Japanese, Chinese, and Caucasian ParticipantS (ATLAS)

NCT07361354
View directory record Official record
Conditions
Healthy Participants, Pharmacokinetic Study
Interventions
AGA2118
Drug
Lead sponsor
Angitia Incorporated Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Jun 7, 2026, 1:30 PM EDT
Completed Phase 1 Interventional

A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors

NCT00907205
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumors, Cancer, Solid Cancers
Interventions
SF1126
Drug
Lead sponsor
Semafore Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
4
States / cities
Scottsdale, Arizona • Tucson, Arizona • Atlanta, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2013 · Synced Jun 7, 2026, 1:30 PM EDT
Completed Phase 1 Interventional

Pharmacokinetic Study of Dexmedetomidine After Intra-Nasal and Buccal Dosing in Children

NCT03668951
View directory record Official record
Conditions
Heart Diseases
Interventions
Dexmedetomidine buccal, Dexmedetomidine Intranasal
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Months to 48 Months
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced Jun 7, 2026, 1:30 PM EDT
Completed Phase 1 Interventional

A Safety And Pharmacokinetic Study With CVX-045 In Patients With Advanced Solid Tumors

NCT00879554
View directory record Official record
Conditions
Advanced Solid Tumors, Neoplasms, Carcinoma, Cancer, Malignancy
Interventions
CVX-045
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
3
States / cities
Scottsdale, Arizona • Santa Monica, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 12, 2010 · Synced Jun 7, 2026, 1:30 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of EDP-788

NCT02255968
View directory record Official record
Conditions
Healthy
Interventions
EDP-788, Placebo
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 11, 2015 · Synced Jun 7, 2026, 1:30 PM EDT
Completed Phase 4 Interventional Results available

Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma

NCT00414765
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma, Metastatic Melanoma
Interventions
Aldesleukin
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
4
States / cities
Los Angeles, California • Aurora, Colorado • Louisville, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Jun 7, 2026, 1:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic and Pharmacodynamic Effects of Passive Cannabis Inhalation

NCT01798186
View directory record Official record
Conditions
Cannabis Toxicology
Interventions
Cannabis
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 45 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 2, 2017 · Synced Jun 7, 2026, 1:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating BLI-489 and Piperacillin in Healthy Subjects

NCT00894439
View directory record Official record
Conditions
Healthy Subjects
Interventions
BLI-489/Piperacillin, BLI-489, Piperacillin
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 16, 2009 · Synced Jun 7, 2026, 1:30 PM EDT